A pharmacogenetic versus a clinical algorithm for warfarin dosing. - Wikidata - wikimedia - TriplyDB

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

http://www.wikidata.org/entity/Q37616712

about

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Economic evaluations of personalized medicine: existing challenges and current developments Cardiovascular pharmacogenomics: current status and future directions Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Pharmacogenetics-based warfarin dosing in children Pharmacogenomics of hypertension and heart disease Use of contemporary genetics in cardiovascular diagnosis Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis Respiratory review of 2014: pulmonary thromboembolism Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism Challenges to integrating pharmacogenetic testing into medication therapy management Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity News from the NIH: potential contributions of the behavioral and social sciences to the precision medicine initiative A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics Progress towards the integration of pharmacogenomics in practice Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association APOE ε variants increase risk of warfarin-related intracerebral hemorrhage.Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements.Use of genetic data to guide therapy in arterial disease.Analyzing the potential for incorrect haplotype calls with different pharmacogenomic assays in different populations: a simulation based on 1000 Genomes data.New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting.STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression.An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D.Genetic-based prediction of disease traits: prediction is very difficult, especially about the future Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Edoxaban: an update on the new oral direct factor Xa inhibitor.Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?Pharmacogenetics of heart failure.Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses Implementation and utilization of genetic testing in personalized medicine.Drug-gene interactions: inherent variability in drug maintenance dose requirements Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

P2860

Q26787099-E56B44CB-A9BA-47D9-BDE9-800FAA1910B7 Q26797183-6D3B8347-E16E-4395-9366-A921298FCDE6 Q26801183-4268B2C1-CE77-4C04-9B0E-0AC102AB27F2 Q26822796-932C0018-51B0-43D5-A771-CCADE5CE1F68 Q27008320-0872EAFF-2359-48C7-9462-125A37B4DAF5 Q27015722-29D3E1C8-8FE2-4891-A3B0-21DC50D7A119 Q27025306-8CBEE16E-A938-4622-B8E8-109702B9AAF8 Q27026134-D5BF09AA-430A-42EC-B6C9-CC0C45AAB158 Q27028131-2C1D9793-B8AE-43A2-BA0C-2FFFC712A09A Q27335306-0842C9F0-B3C6-45E2-A3E1-D663DEAAD8CB Q28066527-7AC73F5C-D627-43BA-BD8E-727FCBB6FC87 Q28082835-489A3F60-A379-4AE6-B0F0-D699C89A0AB5 Q28083100-9C44D3D0-DBF5-4F01-B923-4E90C51B21C3 Q28385820-C83609A1-5222-452D-AA66-4A71DF0D9E9C Q28468503-C8C12FD8-4D32-4906-8528-5CAA3C6D7796 Q28601852-2B841A59-D082-47A1-9052-114F1BD2B041 Q28650281-640A9B2F-D117-452E-BDB0-54F68E09B5A5 Q28652270-E4E3D064-EE79-429B-82DD-0C6B4B704C38 Q30359686-14812171-9204-4593-97EC-4EE8EB2C999F Q30370833-2DA27B3D-C200-408D-BA33-5AEDFA9C3B72 Q30699715-F1F4FDA5-D808-4793-BBDD-D07F4D5C6792 Q30978916-F6F971FB-C83E-4C4E-9DF0-AD7A3649939D Q30999121-D66ED866-BBE3-4862-85F3-815DB55A75C8 Q33364524-F4C271DC-4138-4AA3-936B-52AF6876D11E Q33557032-E9B9DC52-047C-4BF9-B4A1-0CCBF93FD243 Q33570878-E8024DAD-0B77-4A40-8366-EC268EE326A0 Q33651712-69C59521-3ECF-4710-82F6-ACFC7AD0B846 Q33693846-0E1D7653-E23F-4EEE-8481-0218EB46D453 Q33760056-9F86B3CE-1A4A-4C76-B7A0-A4D5FC06EC0F Q33770184-902A0726-D961-49D5-9768-7BA11B9CED4C Q33935409-918C71B5-4CAF-4E58-8909-A886BE643E69 Q33946309-8AAAF12D-226E-43E5-B16E-007D352D01BE Q33986293-06C34656-56C1-43F7-8C95-6CBB23BAA3B5 Q34078825-FB2528E4-FDC0-404D-B075-47725C47E306 Q34147916-D2FD3E24-ED43-48AC-89B2-A7C645EA3E65 Q34154939-EBDA58BB-7B9B-4482-A7E9-FB10446C47D7 Q34284362-D1D0885A-F395-4858-913F-79975C3DD313 Q34295187-69CAEE74-D105-4B0B-87F3-8428BE298CF1 Q34402967-5FAADE47-ADD1-464C-853D-9462E09094CF Q34436061-4D2080D3-D1B9-4F19-BC39-EDBEDD9325C8

P2860

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

http://www.wikidata.org/entity/Q37616712

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@en

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@nl

type

label

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@en

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@nl

prefLabel

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@en

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@nl

P1433

Q37616712-7A7CAC2B-F286-4D6F-93C1-35080AF584F7

P1476

Q37616712-598A7ED2-004F-4990-8F61-8FB8BC246057

P2093

Q37616712-01188104-8F7C-46D4-A110-5F516FCADA07

Q37616712-0C209D4A-874B-4EFD-AF28-82C4B21C995F

Q37616712-1225A35B-7FE0-4FC6-9D2E-E3A9095AA07D

Q37616712-17E711E7-DEDC-4212-9BD5-CE497044A875

Q37616712-19228D64-0EC9-4EE3-9399-B8F5F264D50D

Q37616712-29881D98-99D7-4FAB-853A-44E7DB6CF483

Q37616712-3DDC652C-680B-4145-9187-607789BEF361

Q37616712-62A14769-49F4-4702-A602-61E1D6F4DBEF

Q37616712-749FD11B-94A8-482C-84E2-C4F8788DC49D

Q37616712-831B6EF2-F9A4-4DE8-AFBD-2E0BC42BA317

P2860

Q37616712-0E0F0FD0-5852-4B10-9605-55D046EAB771

Q37616712-176F2917-82E6-459D-8756-375DF2A0E494

Q37616712-1C1CB1C3-63BB-46F0-82B1-F8EA60AB88D7

Q37616712-2E892373-77FE-4E5E-9061-8B251C6DFAE6

Q37616712-350AA88E-F349-4542-8407-CFD2D0ABB3CE

Q37616712-39113DFE-E24C-44E8-90D4-8322EAF975FA

Q37616712-3995B6C9-CAA0-4E8B-A87F-97AA6989B1D1

Q37616712-3AB1FF0D-0E5C-4F52-B38E-A8D5DF1A5F16

Q37616712-40F1F51B-3370-4857-924B-B1FE5CDFE6D6

Q37616712-44EFAD76-6689-4412-BA53-23839568DB15

P304

Q37616712-ADE711F7-9D1B-4237-8BD7-E0FA3D343902

P31

Q37616712-25FDC083-E7FD-4340-894A-BEA9DA6D8838

P356

Q37616712-3AA9A5B7-2178-4A73-9E91-931ECAF9598B

P407

Q37616712-34AD6788-2797-4502-B711-DC143C08029D

P433

Q37616712-05EAA17B-0879-4A0C-9DB1-A2FFAF4C15FF

P478

Q37616712-F1F00486-CCD7-49BF-A51D-BFD8901C6B78

P50

Q37616712-436277EA-3716-4FFB-8FE8-8A6361DEF800

Q37616712-D0D53BFE-AD42-4771-ADDD-C394DE6CAF0F

Q37616712-EC1A404F-13AE-4BED-8A32-77D95F008A58

Q37616712-EC1E9B35-8860-4FE5-8969-7A1CEF7C501B

P577

Q37616712-734D4410-CF1B-4A8A-957A-8E290291F78C

P698

Q37616712-C2A45A1F-1881-4836-AB3C-05C9A474C79D

P932

Q37616712-D7204F76-2E60-4E4A-93AE-65FB129252B4

P356

P1433

The New England Journal of Medicine

P1476

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

@en

P2093

Benjamin French

http://www.w3.org/2001/XMLSchema#string

Brian F Gage

http://www.w3.org/2001/XMLSchema#string

COAG Investigators

http://www.w3.org/2001/XMLSchema#string

Charles S Eby

http://www.w3.org/2001/XMLSchema#string

Emile R Mohler

http://www.w3.org/2001/XMLSchema#string

Henny H Billett

http://www.w3.org/2001/XMLSchema#string

James A S Muldowney

http://www.w3.org/2001/XMLSchema#string

Jaspal Gujral

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Anderson

http://www.w3.org/2001/XMLSchema#string

Jonas H Ellenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Genetics and cardiovascular disease: a policy statement from the American Heart Association.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Integration of genetic, clinical, and INR data to refine warfarin dosing.

Debating clinical utility

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

Idraparinux versus standard therapy for venous thromboembolic disease.

Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

P304

2283-2293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1310669

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Patrice Delafontaine

Robert D McBane

Jonathan L. Halperin

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24251361

http://www.w3.org/2001/XMLSchema#string

P932

3942158

http://www.w3.org/2001/XMLSchema#string